August pharmaceutical events list: the vitality of domestic pharmaceutical enterprises continue to emerge

"Pharmaceutical Network Industry Dynamics" August is the major listed companies in the mid-quarter report disclosure of the intensive period.
the same time, the pharmaceutical industry's various lists are also published intensively.
From the list released by the author in August, including the 2019 National Pharmaceutical Industry Top 100 list, 2019 China's drug distribution industry retail top 100 list, 2019 China's top 100 drugstore chain list, 2020 Fortune 500 list, Forbes health rich list, such as a rich list, the vitality of domestic pharmaceutical companies continue to emerge, it is worth recalling.
2019 National Pharmaceutical Industry Top 100 List was released on August 30, 2020 (37th) National Pharmaceutical Industry Information Annual Meeting hosted by the China Pharmaceutical Industry Information Center and the 2019 China Pharmaceutical Industry Top 100 List Launch will be held in Zhuhai.
business income of the top 100 companies in 2019 reached 929.64 billion yuan, a growth rate of 10.7%, exceeding the overall growth rate of the pharmaceutical industry by 2.7 percentage points.
from the top 10 list, Yangzijiang Pharmaceutical Group Co., Ltd., Guangzhou Pharmaceutical Group Co., Ltd., China Pharmaceutical Group Co., Ltd. ranked in the top three, three enterprises, the main business income exceeded 40 billion scale.
and Evergrande Group and Hengrui Pharmaceuticals entered the top 10 for the first time, ranking ninth and 10th, respectively.
market capitalisation rankings for Hong Kong stocks have been published as of August 26, 2020.
from the top 50 list, the change in the ranking of Pharmaceutical Life is very obvious, from the original 36 to 29, up seven places, the current market value of HK$255.851 billion.
on August 27th, the stock rose more than 6 per cent to a record high.
in late August, the China Pharmaceutical Business Association officially released the "Top 100 Retail Enterprises in China's Drug Circulation Industry in 2019".
Among them, the top five are Guoda Pharmacy Co., Ltd., The People's Big Pharmacy Chain Co., Ltd., DasinLin Pharmaceutical Group Co., Ltd., Yiyitang Pharmaceutical Group Co., Ltd., Yifeng Da Pharmacy Chain Co., Ltd.
as of December 31, 2019, all five companies had annual revenues of more than $10 billion.
the 2020 Fortune 500 in August and the Fortune 500 in 2020.
According to the list, there are 13 pharmaceutical companies in the pharmaceutical industry, including three Chinese pharmaceutical companies, namely China Resources (79th), China Pharmaceutical Group (145th) and Shanghai Pharmaceuticals (473rd).
Johnson and Johnson are still in the top two for multinational pharmaceutical companies, but the third place is held by Bayer, replacing the original Pfizer position (Pfizer is currently down 17 places).
2019 China's top 100 drugstore chain on August 13, china Pharmaceutical Business Association officially released China's pharmaceutical industry top 100, China's top 100 pharmaceutical business, China's top 100 pharmaceutical chain, China's pharmaceutical industry growth of the top 50, China's pharmaceutical research and development (outsourcing) companies top 20, China's pharmaceutical industry top 10 new figures, China's medical device technology innovation enterprises and a series of lists.
Among them, "2019 China's top 100 drugstore chain list", the top three are the National University pharmacy, the people's big pharmacy, the big ginseng forest, followed by the heart of the hall ranked fourth, Yifeng big pharmacy ranked fifth.
china's medical unicorn rankings were made public in early August, Hurun Research Institute released the "Suzhou High-energy Zone 2020 Hurun Global Unicorns List."
lists non-listed companies valued at more than $1 billion as of March 31, 2020.
, 47 unicorn companies involved in the field of medical and health care were listed in the biotechnology and health technology sub-sectors.
, China has 22 more companies than the U.S. 18.
7 Chinese companies in the biotechnology industry, while china's advantage in the health technology industry is even more pronounced, with 16 companies outnstrsting the U.S. 11.
the forbes health rich list was released on the evening of August 4, Forbes China released the forbes health rich list of the top 50.
according to Forbes' list of China's richest people in healthcare, Zhong Huixuan, the 59-year-old chairman of Hanson Pharmaceuticals' board of directors, topped the list with $19.5 billion ($136.15 billion).
In addition, Meirui Medical co-founder Li Xiting ($17.5 billion), Hengrui Pharmaceutical Group Chairman Sun Fengyang ($16.8 billion), Meirui Medical co-founder Xu Hang ($16.3 billion), Zhifei Bio Jiang Rensheng and family ($16 billion) are all in the top five.